Here are the latest takes on both the progress and the pitfalls of continuous manufacturing adoption in biopharma, exclusively from Bioprocess Online.
- Learn what's working, what's not, and why in a collaborative report authored by Richard Chen (Eli Lilly and Company), Chris Hwang (Transcenta Holding Ltd.), Kelvin Lee (NIIMBL), Andrew Zydney (The Pennsylvania State University), and John F. Kokai-Kun (The United States Pharmacopeia).
- Wonder how continuous manufacturing compares with batch processing in terms of environmental impact and resource consumption? Get answers from John F. Kokai-Kun (The United States Pharmacopeia) in a comprehensive two-parter on the topic.
- Find out what went wrong for biopharma continuous manufacturing pioneer Parrish Galliher, now an independent bioprocess consultant, and learn how to avoid making the same mistakes.
- Is your regulatory effort going global, or planning to? Catch up on the latest (final?) Q13 guidance from ICH with Nathan Parker, Principal Consultant, Parker Biopharmaceutical Consulting.
Where else can you get such a complete and current take on continuous manufacturing in biopharmaceutical environments, all in one package, from seven of the leading minds on the topic?